



Document heading doi: 10.1016/S2305-0500(13)60122-0

Two case studies assessing the effect of oral contraceptive pills upon serum AMH concentrations: Results from an external quality assurance (EQA) scheme

Emily Zuvella^{1,2*}, Melanie Walls², Phillip Matson^{3,4}

¹External Quality Assurance Schemes for Reproductive Medicine, PO Box 162, Northlands WA 6905, Australia

²Fertility Specialists of Western Australia, Bethesda Hospital, 25 Queenslea Drive Claremont WA 6010, Australia

³Fertility North, Suite 213, Specialist Medical Centre, Joondalup Health Campus, Shenton Avenue, Joondalup WA 6027, Australia

⁴Edith Cowan University, 270 Joondalup Drive, Joondalup WA 6027, Australia

ARTICLE INFO

Article history:

Received 12 February 2013

Received in revised form 20 February 2013

Accepted 23 February 2013

Available online 20 March 2013

Keywords:

AMH

Oral contraceptives

ABSTRACT

Objective: To describe the effect of combined oral contraceptives (COC) on serum AMH level in 2 women. **Methods:** The COC was initially stopped after over 12 years use then restarted, with the serum being analysed by 6–8 laboratories in an EQA scheme using the same assay (Beckman Coulter Gen II). **Results:** In both women, the AMH rose significantly after cessation of the pill, and then dropped after resumption. **Conclusions:** In summary, AMH was affected by the combined oral contraceptive pill and further studies on the effect of oral contraceptives are warranted.

1. Introduction

Anti-müllerian hormone (AMH) has been shown to be a useful marker of ovarian reserve [1]. With its increasing clinical utility, attention has been paid to different clinical situations that might affect the AMH levels and hence their interpretation. The use of oral contraceptives was of interest given the suppression of ovarian follicular development and ovulation seen with often different forms of the pill [2]. AMH concentrations were not thought to be modified by the use of oral contraceptives [3, 4] allowing ovarian reserve to be assessed whilst women were still on the pill, but this is not universally held as other reports have shown oral contraceptives to have a suppressive action [5–8]. The present report describes the experience of an external quality assurance scheme for AMH in which samples were analysed by a number of laboratories, showing longitudinal changes in two women stopping and then resuming oral contraception.

2. Materials and methods

2.1. Blood collection

Blood samples were collected by venepuncture and separated immediately by centrifugation. The serum was allowed to clot at room temperature for 1 hour and the clot removed. Serum was decanted and stored at 4 °C prior to packing, and distributed within 3 days to laboratories participating in the External Quality Assurance Schemes for Reproductive Medicine (EQASRM; Northlands Western Australia 6905). All laboratories used the same assay kit, namely the Beckman Coulter Gen II ELISA (Beckman Coulter Australia Pty Ltd, Gladesville NSW 2111, Australia). Values were compared according to published reference ranges [9–11]. AMH concentrations for each woman were analysed initially by ANOVA using the StatistiXL add-in for Excel (StatistiXL, Nedlands, Western Australia 6009), followed by Tukey's HSD test, and differences considered significant if $P < 0.05$.

2.2. Subjects

The first case was a 26 year old female, non-smoking, volunteer in good health, with no previous pregnancies, having a normal BMI, without any history of polycystic ovarian disease, and no family history of premature ovarian

*Corresponding author: Mrs Emily Zuvella, External Quality Assurance Schemes for Reproductive Medicine, PO Box 162, Northlands WA 6905, Australia.
E-mail: info@eqasm.com.au

failure or infertility. She had regular menstrual cycles before starting oral contraception, having commenced Micryogynon 30 (Ethinylestradiol, Levonorgestrel; Bayer Schering Pharma, Pymble NSW 2073, Australia) 12 years earlier for contraceptive purposes.

Case 2 was a 41 year old female volunteer with no previous pregnancies, a non-smoker with normal body mass index. However, she had previously been diagnosed with polycystic ovarian disease, with elevated androgens and oligomenorrhea, for which she had been taking Diane-35 (Ethinylestradiol, Cyproterone acetate; Bayer Schering Pharma, Pymble NSW 2073, Australia) for 14 years.

3. Results

Blood was taken when they had been off the pill for 1 month and 3 months, and then 3 months after resuming the pill. Serum samples were sent to 6–8 laboratories in each distribution, and all laboratories used the Beckman Coulter Gen II ELISA.

The AMH concentrations for the two women when on and off the pill are shown in Table 1. There were significant differences overall for each woman. Both women had levels consistent with reduced ovarian reserve after being on the pill for 12 years or more. Subsequent post hoc analysis showed that there were increases in the concentration once coming off the pill, becoming significant after 3 months. Once resuming the pill, AMH had returned to levels similar to the baseline values after 3 months.

Table 1

Serum AMH concentrations (mean \pm sem) for two women on the pill for 12 or more years.

Medication	Time on or off medication	AMH concentration (pmol/L)	
		Case 1 ^a	Case 2 ^b
Pill	≥ 12 years	7.8 \pm 0.6	6.6 \pm 0.8
None	1 month	11.6 \pm 1.0	3.8 \pm 0.3
	3 months	23.2 \pm 1.5*	17.4 \pm 2.0*
Pill	3 months	11.7 \pm 0.9	3.9 \pm 0.3

Data were expressed as Mean \pm SEM. ^aMicryogynon 30 ; ^bDiane-35; * $P < 0.001$ vs the baseline figure on the pill.

4. Discussion

Many women in their reproductive years use oral contraception, and two main reasons for the measurement of AMH to measure functional ovarian reserve in such women have been proposed. Firstly, prolonged use of the contraceptives can suppress pituitary gonadotrophins and antral follicle development thereby creating an experimental opportunity to evaluate AMH as a marker of ovarian reserve rather than follicular growth^[12]. Secondly, a clinical test in users of hormonal contraceptives for the differential diagnosis of anovulatory disorders and early menopause would be useful, and AMH would be an ideal candidate if it was found to be unaffected by oral contraceptives^[13]. The effect of oral contraceptives on AMH in a number of clinical settings is unclear from the literature. Women with polycystic ovarian syndrome show either no change in AMH level after hormonal contraception^[14] or a reduction^[5], as do normally cycling women with no change^[4, 12, 13, 15] or a reduction^[7, 8, 16]. The present report has shown two case studies chosen at random that both demonstrate an increase in AMH when coming off the oral contraception followed by a reduction when the contraception was resumed. Further studies examining the effect of different pharmaceutical preparations in women of varying ovarian reserve would

seem warranted.

Conflict of interest statement

We declare that we have no conflict of interest.

References

- [1] Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-müllerian hormone from conception to menopause. *PLoS ONE* 2011; **6**: (7) e22024.
- [2] Grimes DA, Godwin AJ, Rubin A, Smith JA, Laccarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. *Obstet Gynecol* 1994; **83**: (1) 29–34.
- [3] La Marca A, Sighinolfi G, Giulini S, Traglia M, Argento C, Sala C, et al. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles. *Reprod Biomed Online* 2010; **21**: (4) 463–469.
- [4] Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. *Fertil Steril* 2008; **90**: (2) 395–400.
- [5] Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. *Gynecol Endocrinol* 2011; **27**: (8) 587–592.
- [6] Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, et al. Serum antimüllerian hormone in healthy premenopausal women. *Fertil Steril* 2011; **95**: (8) 2718–2721.
- [7] Arbo E, Vettori DV, Jimenez MF, Freitas FM, Lemos N, Cunha-Filho JS. Serum anti-müllerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. *Hum Reprod* 2007; **22**: (12) 3192–3196.
- [8] Kallio S, Puurunen J, Ruukonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. *Fertil Steril* 2012 (in press).
- [9] Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-müllerian hormone as a marker of ovarian reserve. *Aust N Z J Obstet Gynaecol* 2005; **45**: (1) 20–24.
- [10] Friden B, Sjöblom P, Menezes J. Using anti-Müllerian hormone to identify a good prognosis group in women of advanced reproductive age. *Aust N Z J Obstet Gynaecol* 2011; **51**: (5) 411–415.
- [11] Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. *Fertil Steril* 2009; **92**: (5) 1586–1593.
- [12] Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. *Ultrasound Obstet Gynecol* 2012; **39**: (5) 574–580.
- [13] Li HWR, Wong CYG, Yeung WSB, Ho PC, Ng EHY. Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives. *Contraception* 2011; **83**: (6) 582–585.
- [14] Somunkiran A, Yavuz T, Yuçel O, Özdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol* 2007; **134**: (2) 196–201.
- [15] Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimüllerian hormone and obesity: insights in oral contraceptive users. *Contraception* 2010; **81**: (3) 245–248.
- [16] van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JWR, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. *Hum Reprod* 2010; **25**: (6) 1520–1527.